Bio & Pharma
EuBiologics gets WHO certification for cholera vaccine facility
The company's Chuncheon Plant No. 2 vaccine bulk production plant obtained WHO prequalification certification
By May 17, 2024 (Gmt+09:00)
1
Min read
Most Read
S.Korea's LS Materials set to boost earnings ahead of IPO process
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Macquarie eyes its 1st Korean data center valued around $722 mn
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
SK Inc. in talks to sell Pharmteco’s US CDMO plant to Novo Nordisk
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Galaxy Ring, new foldables set to steal the show at Samsung Unpacked Paris
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
POSCO gears up for carbon-free steelmaking with hydrogen
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
![EuBiologics gets WHO certification for cholera vaccine facility](https://www.kedglobal.com/data/ked/image/2024/05/17/ked202405170024.500x.0.jpg)
WHO-PQ is a system that evaluates the manufacturing process, quality, and clinical results of vaccines to certify their safety and efficacy.
WHO-PQ certification is mandatory to participate in global bids arranged by UN agencies such as UNICEF and the Pan American Health Organization.
With this certification, EuBiologics reported that it could increase its production of cholera vaccine bulk by over 60% compared to last year.
Until now, the manufacturing of cholera vaccine bulk was only available at Chuncheon Plant No. 1.
Write to Yena Kim at yena@hankyung.com
More to Read
-
Bio & PharmaEuBiologics, GC Biopharma to jointly produce cholera vaccine
Aug 25, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaS.Korea's EuBiologics to receive support from Gates Foundation
Feb 23, 2023 (Gmt+09:00)
1 Min read
Comment 0
LOG IN